Cesar O Freytes

• Professional Background

  Education

  • 1985 - Clinical Fellowship - Hematology/Oncology - Washington University
  • 1981 - Residency - Medicine - San Juan VAMC, PR
  • 1979 - Internship - Medicine - San Juan VAMC, PR
  • 1979 - MD - Internal Medicine - University of Puerto Rico School of Medicine
  • 1976 - BS - Biology - University of Puerto Rico

  Appointments

  • 9/2004 - Professor and Director: Adult Hematopoeitic Stem Cell Transplant Program - UTHSCSA, Medicine, San Antonio
  • 11/1991 - Staff Physician - Cancer Therapy and Research Center, Medicine, San Antonio
  • 11/1991 - Consultant - Southwest Texas Methodist, Medicine, San Antonio
  • 11/1991 - Staff Physician - ALMMVH, Medicine, San Antonio
  • 11/1991 - Staff Physician - University Hospital, Medicine, San Antonio

• Instruction & Training

  • - Present, Individual Instruction, VA Hospital and UTHSCSA
  • 10/2010 - Present, Fellow Lecture, UTHSCSA
  • 9/2007 - Present, Medicine Grand Rounds, UTHSCSA
  • 9/2007 - Present, Housestaff Conference, UTHSCSA
  • 1/2004 - Present, Outpatient Bone Marrow Transplant, UTHSCSA
  • 9/2000 - Present, Housestaff Conference, UTHSCSA
  • 8/2000 - Present, Housestaff conference, UTHSCSA
  • 8/2000 - Present, Housestaff conference, UTHSCSA
  • 5/2000 - Present, Housestaff conference, UTHSCSA
  • 3/2000 - Present, Housestaff conference, UTHSCSA
  • 1/2000 - Present, Hematology Service, UTHSCSA
  • 1/2000 - Present, Hematology clinic, UTHSCSA
  • 1/2000 - Present, Hematology Service, UTHSCSA
  • 1/2000 - Present, Outpatient BMT, UTHSCSA
  • 1/2000 - Present, Hematology clinic, UTHSCSA
  • 12/1999 - Present, Intro to Clin Medicine, The University of Texas Health Science Center
  • 12/1999 - Present, Intro to Clin Medicine, The University of Texas Health Science Center
  • 11/1999 - Present, Intro to Clin Medicine, The University of Texas Health Science Center
  • 5/1999 - Present, Oncology Research Conference, UTHSCSA
  • 3/1999 - Present, Housestaff Conference, UTHSCSA
  • 2/1999 - Present, Intro to Clinical Medicine, The University of Texas Health Science Center
  • 2/1999 - Present, Intro to Clinical Medicine, The University of Texas Health Science Center
  • 1/1999 - Present, Hematology clinic, UTHSCSA
  • 1/1999 - Present, Hematology service, UTHSCSA

• Research & Grants

  Grants

  Private

  Funding Agency
  Otsuka Pharmaceutical

  Title
  A Multi-enter, Phase 2, Single-Arm, open-label exploratory study of individually-optimized conditioning using pharmacokinetics (PK)-direct dose adjustment of once daily intravenous busulfan. Followed by autologous hematopoietic stem cell transplant in su

  Status
  Active

  Period
  9/2009 - Present

  Role
  Principal Investigator

  Grant Detail
   

  Funding Agency
  FlaxoSmithKline

  Title
  Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in relapsed or refractory DLBCL

  Status
  Active

  Period
  11/2009 - Present

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
  Otsuka Pharmaceutical

  Title
  A Phase 2a study of once daily intravenous busulfan with bortezomib. Followed by an autologous hematopoietic stem cell transplant (HSCT) in subjects with relapsed multiple myeloma after prior autologous HSCT

  Status
  Active

  Period
  4/2010 - Present

  Role
  Co-Investigator

  Grant Detail
   

  Funding Agency
  Kabi-Pharmacia

  Title
  A Randomized Phase III Double-Blind Study of the Use of Linomide vs. Placebo Following Autologous Bone Marrow Transplantation for the First or Subsequent Remission Complete Remission in Acute Myelogenous Leukemia

  Status
  Active

  Period
  11/1993 - Present

  Role
  Principal Investigator

  Grant Detail
   

  Funding Agency
  Independent research

  Title
  A multicenter phase II study of rituximab in patients with CD20 positive intermediate-grade and select high-grade non-hodgkin's lymphoma who have relapsed after high-dose chemotherapy and autologous stem cell transplantation.

  Status
  Active

  Period
  5/2000 - Present

  Role
  Co-Investigator

  Grant Detail
  A multicenter phase II study of rituximab in patients with CD20 positive intermediate-grade and select high grade non-Hodgkin's lymphoma who have relapsed after high-dose chemotherapy and autologous stem cell transplantation.

  Funding Agency
  CellPro, Inc.

  Title
  A Prospective Randomized Phase III Study Using CEPRATE SC Stem Cell Concentrator to Concentrate Hematopoietic Progenitors for Use in hematopoietic Support After High Dose Chemotherapy

  Status
  Active

  Period
  7/1992 - Present

  Role
  Principal Investigator

  Grant Detail
   

   

  Funding Agency
  Human Genome Sciences

  Title
  A multicenter, rising-dose, randomized double-blinded study vehicle controlled study of intravenous KGF-2 in subjects at risk of developing mucositis secondary to the action of conditioning regimens for autologous hematopoietic stem cell transplantation.

  Status
  Active

  Period
  3/2000 - Present

  Role
  Principal Investigator

  Grant Detail
  A multicenter, rising-dose, randomized double-blinded study vehicle controlled study of intravenous KGF-2 in subjects at risk of developing mucositis secondary to the action of conditioning regimens for autologous hematopoietic stem cell transplantation.